In this study, we examined the relationship between increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic changes, and susceptibility to subsequent spontaneous recurrences of methamphetamine (MAP) psychosis (i.e., flashbacks). The subjects were 81 physically healthy females. Plasma monoamine metabolite levels were assayed in: 19 flashbackers, of whom 11 experienced a single flashback and 8 exhibited subsequent flashbacks; 20 non-flashbackers with a history of MAP psychosis; 8 subjects with persistent MAP psychosis; and 23 MAP users and 11 non-user controls. All 19 flashbackers had undergone frightening and stressful experiences during previous MAP use. Mild psychosocial stressors then triggered their flashbacks. During flashbacks, plasma norepinephrine levels increased, with a small increase in plasma levels of 3-methoxytyramine, which is an index of dopamine release. Among the 19 flashbackers, the 8 with subsequent episodes had increased NE levels and slightly increased 3-methoxytyramine levels, while the 11 with a single episode displayed small increases in norepinephrine and 3-methoxytyramine levels. Thus, noradrenergic hyperactivity and increased dopamine release in response to mild psychosocial stressors may be responsible for the development of flashbacks. Robust noradrenergic hyperactivity with slightly increased DA release in response to mild stress may induce susceptibility to subsequent flashbacks. Flashbacks and schizophrenia may share the pathophysiology of susceptibility to recurrence of paranoid-hallucinatory states such as stress sensitization, and also noradrenergic hyperactivity and enhanced DA release. Thus, flashbacks may provide an appropriate model of susceptibility to paranoid-hallucinatory states of schizophrenia. The model psychosis is a potential tool for validating basic neurobiological concepts thought to be related to the schizophrenia. A better understanding of the neurobiological mechanisms of susceptibility to recurrence could provide useful information in the development of strategies for preventing relapse.
References
1
Abercrombie E D, Jacobs B L.
Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. 1. Acutely presented stressful and nonstressful stimuli.
J Neurosci.
1987;
7
2837-2843
2
Andermann L F, Savard G, Meencke H J, McLachlan R, Moshé S, Andermann F.
Psychosis after resection of ganglioglioma or DENT: evidence for an association.
Epilepsia.
1999;
40
83-87
3
Anisman H, Zacharko R M.
Behavioral and neurochemical consequences associated with stressors.
Ann NY Acad Sci.
1995;
771
205-225
4
Asaad G, Shapiro B.
Hallucinations: theoretical and clinical overview.
Am J Psychiatry.
1986;
143
1088-1097
5
Bell D S.
Comparison of amphetamine psychosis and schizophrenia.
Br J Psychiatry.
1965;
111
701-707
6
Breier A, Buchanan R W, Waltrip II R W, Listwak S, Holmes C, Goldstein D S.
The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.
Neuropsychopharmacology.
1994;
10
1-7
7
Bremner J D, Krystal J H, Southwick S M, Charney D S.
Functional neuroanatomical correlates of the effects of stress on memory.
J Traumatic Stress.
1995;
8
527-553
8
Brown A S, Gewirtz G, Harkavy-Friedman J, Cooper T, Brébion G, Amador X F, Malaspina D, Gorman J M.
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Neuropsychopharmacology.
1987;
17
317-325
9
Castellani S, Ziegler M G, van Kammen D P, Alexander P E, Siris S G, Lake C R.
Plasma norepinephrine and dopamine-β-hydroxylase activity in schizophrenia.
Arch Gen Psychiatry.
1982;
39
1145-1149
10
Charpusta S J, Wyatt R J, Masserano J M.
Effects of single and repeated footshock on dopamine release and metabolism in the brains of fisher rats.
J Neurochem.
1997;
68
2024-2031
11
Dalmaz Y, Peyrin L.
Relations entre la 3-méthoxytyramine urinaire et le metabolisme péripherioque de la dopamine chez l'homme et chez l'enfant.
Archiv Inter Physiol Biochim.
1978;
86
257-270
12
Dimsdale J E, Moss J.
Plasma catecholamines in stress and exercise.
JAMA.
1980;
243
340-342
13
Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H.
History, rationale and potential of human experimental hallucinogenic drug research in psychiatry.
Pharmacopsychiatry.
1998;
31
(2 Suppl)
63-68
14
Green A I, Alam M Y, Boshes R A, Waternaux C, Pappalardo K M, Fitzgibbon M E, Tsuang M T, Schildkraut J J.
Haloperidol response and plasma catecholamines and their metabolites.
Schizophr Res.
1993;
10
33-37
15 Havilcek L L, Crain R D. Practical statistics for physical sciences. American Chemical Society, Washington DC 1988
16
Heal D J, Frankland A TJ, Buckett W R.
A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detention studies with drugs which alter dopamine metabolism in the brain.
Neuropharmacology.
1990;
29
1141-1150
17
Holroyd S H, Rabins P, Finkelstein D, Nicholson M C, Chase G A, Wisniewski S C.
Visual hallucinations in patients with macular degeneration.
Am J psychiatry.
1992;
149
1701-1706
18
Holsten F.
Flashbacks: a personal follow-up.
Arch Psychiatr Nervenkr.
1976;
222
293-304
19
Irwin J, Ahiluwalia P, Anisman H.
Sensitization of norepinephrine activity following acute and chronic footshock.
Brain Res.
1986;
379
98-103
20
Javitt D C, Zukin S R.
Recent advances in the phencyclidine model of schizophrenia.
Am J Psychiatry.
1991;
148
1301-1308
21
Kent A P, Stern G M, Webster R A.
The effect of benserazide on the peripheral and central distribution and metabolism of lovodopa after acute and chronic administration in the rat.
Br J Pharmacol.
1990;
100
743-748
22 Landau S L. International dictionary of medicine and biology. A Wiley Medical Publication, New York, Chichester, Brisbane, Toronto, Singapore 1986 III
23
Laruelle M.
The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies.
Brain Res Rev.
2000;
31
371-384
24
Lieberman J A, Kinon B J, Loebel A D.
Dopammergic mechanisms in idiopathic and drug-induced psychoses.
Schizophr Bull.
1990;
16
97-110
25
Lieberman J A, Sheitman B B, Kinon B J.
Neurochemical sensitization in the pathophysiology of schizophrenia: deficit and dysfunction in neuronal regulation and plasticity.
Neuropsychopharmacology.
1997;
17
205-229
26
Maeda S, Miyauchi J, Sakane M, Satto M, Maki S, Goto K, Matsuda M.
Does endothelin-1 participate in the exercise-induced changes of blood flow distribution of muscles in humans?.
J Appl Physiol.
1997;
82
1107-1111
27
Matefy R E, Hayes C, Hirsh J.
Psychedelic drug flashbacks, subjective reports and biographical data.
Addict Behav.
1978;
3
165-178
28
Millns H, Woodward M, Bolton-Smith C.
Is it necessary to transform nutrient variables prior to statistical analyses?.
Am J Epidemiol.
1995;
141
251-262
29
Nagaoka S, Iwamoto N, Arai H.
First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to halopendol treatment.
Biol Psychiatry.
1997;
41
857-864
30
Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G.
The vulnerability/stress model of schizophrenic relapse: a longitudinal study.
Acta Psychiatr Scand.
1994;
89
58-64
31
Ohashi H.
Prison health issues: agenda item 2, the 15th Asian and Pacific Conference of Correctional Administrators (in Japanese).
Japanese Journal of Correction.
1996;
107
36-46
32
Ozawa A.
Normal and abnormal values: Catecholammes. Sogonnsho (in Japanese).
[General Practice of Medicine].
1991;
40
1332-1338
33
Péronnet F, Blier P, Brisson G, Diamond P, Ledoux M, Volle M.
Plasma catecholammes at rest and exercise in subjects with high- and low-trait anxiety.
Psychosom Med.
1986;
48
52-58
34
Petty F, Chae Y -I, Kramer C, Jordan S, Wilson L.
Learned helplessness sensitizes hippocampal norepinephrine to mild restress.
Biol Psychiatry.
1994;
35
903-908
35
Post R M.
Transduction of psychosocial stress into the neurobiology of recurrent affective disorder.
Am J Psychiatry.
1992;
149
999-1010
36
Risbo A, Jessen K, Hagelsten J O.
Catechoiamine response to the clinical use of alpha adrenergic receptor blocking agents.
Acta Anaesthesiol Scand.
1983;
27
72-74
37
Robinson T E, Becker J B, Young E A, Akii H, Castaneda E.
The effects of footshock stress on regional brain dopamine metabolism and pituitary (β-endorphin release in rats previously sensitized to amphetamine.
Neuropharmacology.
1987;
26
679-691
38
Roy A, Pickar D, Jong J D, Karoum F, Linnoila M.
Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine.
Arch Gen Psychiatry.
1988;
45
849-857
39
Sato M, Numachi Y, Hamamura T.
Relapse of paranoid psychotic state in methamphetamine model of schizophrenia.
Schizophr Bull.
1992;
18
115-122
40 Segal D S, Janowsky D S. Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton MA, DiMascio A, Killam KF: Psychopharmacology: a generation of progress. Rave Press, New York 1978: 1113-1123
41
Southwick S M, Krystal J H, Morgan A, Johnson D, Nagy L M, Nicolaou A, Heninger G R, Charney D S.
Abnormal noradrenergic function in posttraumatic stress disorder.
Arch Gen Psychiatry.
1993;
50
266-274
42 Spielberger C D. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press. Palo Alto, California 1983
43
Taylor D C.
Mental state and temporal lobe epilepsy: a correlative account of 100 patients treated surgically.
Epilepsia.
1972;
13
727-765
44
Thurm I, Haefner H.
Perceived vulnerability, relapse risk and coping in schizophrenia: an explorative study.
Eur Arch Psychiatr Neurol Sci.
1987;
237
46-53
45
Tuck J R.
Effects of chlorpromazine, thioridazine and haloperidol on adrenergic transmitter mechanisms in man.
Eur J Clin Pharmacol.
1973;
6
81-87
46
van der Kolk B A, Fisler R.
Dissociation and fragmentary nature of traumatic memories: overview and exploratory study.
J Traumatic Stress.
1995;
8
505-525
47
van Kammen D P.
The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.
Psychol Med.
1991;
21
881-895
48
van Kammen D P, Ågren H, Yao J K, O'Connor D T, Gurklis J, Peters J L.
Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
Am J Psychiatry.
1994;
151
379-384
49
von Voigtlander P F, Burian M A, Althaus T S, Williams L R.
Effects of chronic haloperidol on vitamin E levels and monoamine metabolism in rats fed normal and vitamin E deficient diets.
Res Commun Chem Pathol Pharmacol.
1990;
68
343-352
50
Wang M T, Yoshioka M, Imai K, Tamura Z.
Gas-liquid chromatographic and mass fragmentographic determination of 3-O-methylated catecholamines in human plasma.
Clin Chim Acta.
1975;
63
21-27
51
Westerink B HC, Spaan S J.
On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.
J Neurochem.
1982;
38
680-686
52
Wood P L, Altar C A.
Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons utility of 3-methoxytyramine measurements.
Pharmacol Rev.
1988;
40
163-187
53
Yui K, Goto K, Ikemoto S, Ishiguro T.
Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neuro transmitter function.
J Clin Psychopharmacol.
1997;
17
34-43
54
Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan G E, Sheitman B B, Lieberman J A, Bracha S H, Ali S F.
Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.
Mol Psychiatr.
1999;
4
512-523
55
Yui K, Goto K, Ikemoto S, Ishiguro T.
Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity.
J Clin Psychopharmacol.
2000;
20
165-174
Kunio Yui
Department of Psychiatry, Jichi Medical School
Minamikawachi 3311-1
Tochigi 329-0498
Japan
Phone: +81 (48) 862-7520
Fax: +81 (48) 836-1372
Email: nibrin@jichi.ac.jp